Is there a role for specialized pro-resolving mediators in pulmonary fibrosis?

Thatcher, Thomas H.; Freeberg, M.A.T.; Myo, Yu Par Aung; Sime, Patricia J.

doi:10.1016/j.pharmthera.2023.108460

Pharmacology & Therapeutics

2023

DOI: 10.1016/j.pharmthera.2023.108460

|View full text |Cite

Is there a role for specialized pro-resolving mediators in pulmonary fibrosis?

Thomas H. Thatcher

M.A.T. Freeberg

Yu Par Aung Myo

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

References 166 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

MEOX1 triggers myofibroblast apoptosis resistance, contributing to pulmonary fibrosis in mice

Jin,

Bao,

Huang

et al. 2024

Journal Cellular Physiology

View full text Add to dashboard Cite

The apoptosis resistance of myofibroblasts is a hallmark in the irreversible progression of pulmonary fibrosis (PF). While the underlying molecular mechanism remains elusive. In this study, we unveiled a previously unrecognized mechanism underlying myofibroblast apoptosis resistance during PF. Our investigation revealed heightened expression of mesenchyme homeobox 1 (MEOX1) in the lungs of idiopathic pulmonary fibrosis (IPF) patients and bleomycin‐induced PF mice. Silencing MEOX1 significantly attenuated PF progression in mice. In vitro, we found a notable increase in MEOX1 expression in transforming growth factor‐β1 (TGF‐β1)‐induced myofibroblasts. Silencing MEOX1 enhanced apoptosis of myofibroblasts. Mechanistically, we identified G‐protein signaling pathway regulatory factor 4 (RGS4) as a critical downstream target of MEOX1, as predicted by bioinformatics analysis. MEOX1 enhanced apoptosis resistance by upregulating RGS4 expression in myofibroblasts. In conclusion, our study highlights MEOX1 as a promising therapeutic target for protecting against PF by modulating myofibroblast apoptosis resistance.

show abstract

MEOX1 triggers myofibroblast apoptosis resistance, contributing to pulmonary fibrosis in mice

Jin,

Bao,

Huang

et al. 2024

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

Harnessing anti-inflammatory pathways and macrophage nano delivery to treat inflammatory and fibrotic disorders

Zaid,

Ariel

2024

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease

Fredman,

Serhan

2024

Nat Rev Cardiol

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Is there a role for specialized pro-resolving mediators in pulmonary fibrosis?

Cited by 5 publications

References 166 publications

MEOX1 triggers myofibroblast apoptosis resistance, contributing to pulmonary fibrosis in mice

MEOX1 triggers myofibroblast apoptosis resistance, contributing to pulmonary fibrosis in mice

Harnessing anti-inflammatory pathways and macrophage nano delivery to treat inflammatory and fibrotic disorders

Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease

Contact Info

Product

Resources

About